Intermittent treatment of duodenal ulcer for long term medical management. 1988

K D Bardhan
District General Hospital, Rotherham, UK.

Most patients with duodenal ulcer relapse but in individuals the events is unpredictable and complications are rare. Two methods of long term treatment have been developed: daily maintenance treatment to prevent relapse; and intermittent treatment, in which individual symptomatic relapses are treated with a short healing course. Pooling the results of three studies on intermittent treatment where cimetidine was used, the number of relapses in one year and the proportion of patients who relapsed were: no relapse, 26%; 1 relapse, 33%; 2 relapses, 24%; greater than or equal to 3 relapses, 17%. Thus, 83% of patients on average have less than or equal to 2 attacks per year, which can be rapidly controlled with a short course of treatment. In comparative trials, relapse on maintenance treatment is much less than on intermittent treatment, as would be expected, but the clinical advantage of the former is relatively small and obtained at a much higher cost in drugs. However, in practice, the two treatments are complementary, not competitive, and patients in whom maintenance treatment (or surgery) is necessary would not be considered for intermittent treatment. Most work on intermittent treatment has been done with histamine H2 receptor antagonists. Theoretically, better results might be achieved by increasing the healing rate with omeprazole or more effectively, by reducing the spontaneous relapse rate by healing with colloidal bismuth. Intermittent treatment is contraindicated in the one-third who are either 'high-risk' patients or those who have aggressive ulcer disease. It is suitable for the two-thirds who meet all the following criteria: age <60 years; no associated serious illness; no previous haemorrhage or perforation; not on regular treatment with non-steroidal anti-inflammatory drugs; symptoms develop gradually (se that treatment can be started before pain worsens); less than or equal 2 relapses per year; ulcer is non-refractory. It is essential to establish an accurate diagnosis before starting therapy. Treatment is given for a month and repeated when typical symptoms recur. Repeat endoscopy is not needed except in special circumstances. For the majority of patients, intermittent treatment is an effective, simple and economical way of providing long term treatment.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer

Related Publications

K D Bardhan
January 1980, Hospital practice,
K D Bardhan
January 1991, Acta gastro-enterologica Belgica,
K D Bardhan
January 1988, Postgraduate medical journal,
K D Bardhan
February 1984, Wiener klinische Wochenschrift,
K D Bardhan
June 1984, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
K D Bardhan
January 1990, The Italian journal of gastroenterology,
K D Bardhan
January 1971, Advances in psychosomatic medicine,
K D Bardhan
January 1982, Scandinavian journal of gastroenterology. Supplement,
Copied contents to your clipboard!